ICBP – Supported by Topline Growth
ICBP closed 9M21 with an impressive performance. Despite the implementation of stricter public activity restrictions,
ACES – Slowdown in 3Q21 Sales
ACES closed 3Q21 with disappointing result due to a slowdown in SSSG, as the latest sales figure was negatively impacted
ERAA – Continue on Growth Path
ERAA recorded positive performance sales growth during 3Q21, supported by all business segments. We remain optimistic
MAPI – Recovery in Sight
MAPI booked underwhelming earnings due to negative SSSG in 3Q21. But, this performance was in line with our expectations
MIKA – Facing Earnings Normalization
MIKA continues to booked solid performance in 9M21 with strong growth in both inpatient and outpatient segments. For
MYOR – Margins Suppressed by Higher Raw Material Costs
MYOR’s 3Q earnings and margins came out weak due to higher commodity prices and stricter restriction of public
SIDO – New Products Contribute to Sales Growth
SIDO closed 3Q21 with an impressive sales performance, supported by higher demand in herbal segment and supplements. We
MAPI – Expanding Product Portfolios
MAPI closed 2Q21 with an exciting performance, mainly driven by SSSG improvement and extensive margin expansion. We also
ICBP – Modest Performance amid Declining Margin
ICBP closed 2Q21 with a modest performance, with declining margin across the board due to rising material costs. The
